The U.S. Supreme Court Monday added Helsinn Healthcare S.A. v. Teva Pharmaceuticals USA Inc. to the cases it will hear in its next term, calling into question the Federal Circuit's interpretation of the "on-sale bar" when it comes to drug patent law.